What is Pharnext?
Headquartered in Issy-Les-Moulineaux, France, Pharnext SA specializes in the development of innovative treatments for neurodegenerative conditions, including Charcot-Marie-Tooth disease type 1A and Alzheimer's disease. By leveraging a sophisticated big genetic data and artificial intelligence platform, the company identifies synergistic drug combinations, a methodology known as PLEOTHERAPY. This data-centric approach allows Pharnext to optimize therapeutic efficacy while minimizing development timelines. Beyond its core neurodegenerative focus, the company has demonstrated agility by exploring repurposed drug applications for broader viral threats, positioning itself as a versatile entity within the European biotech landscape.
How much funding has Pharnext raised?
Pharnext has raised a total of $38.6M across 3 funding rounds:
Share Placement
$8.6M
Share Placement
$9.3M
Other Financing Round
$20.7M
Share Placement (2020): $8.6M, investors not publicly disclosed
Share Placement (2021): $9.3M, investors not publicly disclosed
Other Financing Round (2022): $20.7M supported by Néovacs
Key Investors in Pharnext
Néovacs
A French biotechnology company specializing in the development of active immunotherapies for the treatment of autoimmune and inflammatory diseases.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Pharnext?
The infusion of capital from the latest financing round is expected to accelerate the progression of Pharnext's late-stage clinical assets. As the company moves toward potential commercialization, the strategic focus will likely shift toward scaling its AI-driven discovery engine and strengthening its intellectual property portfolio. Investors are closely monitoring the Phase III outcomes for SYNGILITY, which represents a critical milestone for the firm's market entry. By maintaining a rigorous focus on orphan disease indications, Pharnext is well-positioned to capture significant value in the high-barrier-to-entry biopharmaceutical market, provided it continues to navigate the regulatory landscape effectively.
See full Pharnext company page
